Bank of New York Mellon’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Bank of New York Mellon’s Portfolio NVIV Stock Details NVIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,682	Closed	-$67K	–	4561
2021 Q1	$67K	Buy	+2,682	New	+$80.4K	﹤0.01%	4217
2018 Q2	–	Sell	-2	Closed	-$17K	–	4416
2018 Q1	$17K	Hold	2	–	–	﹤0.01%	4279
2017 Q4	$27K	Buy	2 +1	+100%	+$23.1K	﹤0.01%	4283
2017 Q3	$37K	Hold	1	–	–	﹤0.01%	4153
2017 Q2	$70K	Sell	1 -6	-86%	-$328K	﹤0.01%	4090
2017 Q1	$509K	Hold	7	–	–	﹤0.01%	3551
2016 Q4	$538K	Buy	7 +1	+17%	+$89.4K	﹤0.01%	3559
2016 Q3	$771K	Hold	6	–	–	﹤0.01%	3314
2016 Q2	$697K	Hold	6	–	–	﹤0.01%	3367
2016 Q1	$760K	Buy	6 +2	+50%	+$215K	﹤0.01%	3222
2015 Q4	$593K	Sell	4 -1	-20%	-$149K	﹤0.01%	3446
2015 Q3	$740K	Hold	5	–	–	﹤0.01%	3366
2015 Q2	$1.57M	Buy	+5	New	+$1.32M	﹤0.01%	3070

Other funds holding NVIV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of New York Mellon's NVIV Position: Q2 2021 in Review

Bank of New York Mellon sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q2 2021, closing a stake of 2,682 shares — an estimated $67K sold.

Bank of New York Mellon first reported a position in NVIV in Q2 2015 and held it in 13 quarters. The position peaked at $1.57M in Q2 2015. 19 funds tracked by Wall St. Rank hold NVIV as of Q2 2021.

Bank of New York Mellon reported no remaining InVivo Therapeutics Holdings Corp position as of Q2 2021 after selling out during the quarter.
Bank of New York Mellon sold 2,682 InVivo Therapeutics Holdings Corp shares in Q2 2021, an estimated $67K.
Bank of New York Mellon first reported a position in InVivo Therapeutics Holdings Corp in Q2 2015 and held it in 13 quarters.
Bank of New York Mellon's InVivo Therapeutics Holdings Corp position peaked at $1.57M in Q2 2015.
19 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q2 2021.

Based on Bank of New York Mellon's 13F filing for Q2 2021, filed 11 Aug 2021.